The dendrimers and polymer drug conjugates market is anticipated to be worth USD 5 billion by 2026. As defined by the National Nanotechnology Initiative, nanotechnology is the branch of science that deals with materials smaller than 100 nanometers. Notably, the discovery of several nanocarriers such as polymers, proteins, micelles, dendrimers, liposomes, emulsions, nanoparticles, each with a unique structure, has provided the drug developers with options to improve the pharmacokinetics and relea...

The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. According to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. Therefore, there is a pressing need for more specific and poten...

The global CD19 therapeutics market is estimated to grow from USD 8.5 billion in 2024 to reach USD 9.5 billion in 2025 and USD 26.8 billion by 2035, representing a higher CAGR of 10.9% during the forecast period. The pipeline comprises of products across four major classes of drugs, namely, engineered antibodies, bsAbs, ADCs and CAR-T therapies. The major focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. Post initia...

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for 2 or 3 different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. As of now, only 2 bsAbs, Removab and Blincyt...

The specialty CROs market, valued at USD 3.0 billion in 2024, is projected to grow to USD 3.3 billion in 2025 and USD 7.7 billion by 2035, representing a CAGR of 8.9% during the forecast period. Specialty CROs have emerged as credible players in the market to overcome the shortcomings of full service / traditional CROs. Often, these full-service providers offer a wider portfolio of services but fail to align their efforts to meet the requirements of sponsors, primarily the smaller biotech organi...

The global biotherapeutics market is expected to grow from $4.4 billion to $11.0 billion by 2025 at a CAGR of 9.6%. Biopharmaceuticals is currently one of the fastest growing segments in the biopharmaceutical industry. During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. Further, several start-ups, with innovative technologies, have surfaced in the past decade and have contin...

The NASH drugs market, valued at USD 5.7 billion in 2024, is projected to grow to USD 7.7 billion in 2025 and USD 78.2 billion by 2035, representing a CAGR of 26.1% during the forecast period. Given the rising prevalence of NASH, it has become all the more crucial to understand the pathophysiology of NASH in order to develop therapeutic interventions. Several options are being investigated to identify an efficient treatment regimen for NASH; these include lifestyle modifications, off-label thera...

The global immune checkpoint inhibitors market is likely to be worth $25 billion by 2025. It is worth mentioning that recently, the focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

Targeted cancer therapy is an upcoming area gaining strong foothold in the industry and has already become the focus of a number of pharmaceutical companies. Small molecule protein kinase inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases, involved in the growth of cancer cells. In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Ther...

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments. Rare / orphan diseases, as the name suggests, are those diseases which are relatively infrequent in occurrence. The prevalence and adversity of these ailments has gained significant attention in the global healthcare industry. The enactment of the Orphan Drugs Act in the US and EU emerged as ground breaking and provided the necessary support...

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

A significant proportion of the world

Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Statins, though the mainstay therapy for lowering cholesterol, have been associated with some adverse events. These have deterred their use in a subset of population termed as

Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). However, the high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. Notably, there are specific opportunities which remain to be tapped in...

With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. In fact, tn the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in t...